Figure 2.
Comparison of disease onset and clinically relevant recovery rates of visual acuity in arLHON and mtLHON patients. (A) Reported age of onset for arLHON (n = 53, data unavailable for three patients) and mtLHON (n = 104). (B) Clinically relevant recovery rates for idebenone-treated (n = 30) and untreated (n = 16) arLHON patients (data presented for 46 of 56 arLHON patients with follow-up data available over at least 6 months following onset) and idebenone-treated (n = 184) and untreated (n = 88) mtLHON patients.